Skip to main content
Clinical Trials/NCT04676815
NCT04676815
Not yet recruiting
Not Applicable

Application of Narrow Band Imaging (NBI) Under Electronic Bronchoscope in the Diagnosis and Staging of Lung Cancer

Shanghai Pulmonary Hospital, Shanghai, China1 site in 1 country200 target enrollmentJune 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Lung Cancer
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment
200
Locations
1
Primary Endpoint
The specificity of diagnosis of NBI plus electronic bronchoscopy in central type lung cancer
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Narrow-Band Imaging (NBI) is useful to better demarcate the superficial extent of central type of lung cancer, but its sensitivity and specificity in clinical practice were little studied. This study aimed to investigate the diagnostic effects of NBI in suspected patients with central lung cancer and its application in staging diagnosis of central lung cancer.

Detailed Description

With high morbidity and mortality, lung cancer is one of the most common tumors in the world. Therefore, early detection, accurate diagnosis and staging division can effectively guide clinical interventions, thereby improving patient survival. Narrowband imaging under electronic bronchoscope (NBI) is an emerging optical image emphasis technology that can enhance the contrast between the mucosal surface and underlying blood vessels, specifically display the distribution of blood vessels, and highlight the subtle changes in mucosal structure. Meanwhile, it can reduce unnecessary biopsy with low risk and costs. In recent years, NBI technology has gradually begun to show its unique advantages in the diagnosis of gastric cancer, esophageal cancer, nasopharyngeal cancer, and bladder cancer. The purpose of this study is to explore the diagnostic value of NBI under electronic bronchoscopy for early detection and accurate diagnosis of lung cancer, and to provide a more economical, safer and more efficient diagnosis option for lung cancer patients.

Registry
clinicaltrials.gov
Start Date
June 2023
End Date
July 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Responsible Party
Principal Investigator
Principal Investigator

Yayi He

Associate Chief Physician

Shanghai Pulmonary Hospital, Shanghai, China

Eligibility Criteria

Inclusion Criteria

  • Patients had a history or current central lung cancer

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The specificity of diagnosis of NBI plus electronic bronchoscopy in central type lung cancer

Time Frame: 4 months

Abnormal blood vessels or lack of staining is defined as suspected lesions. All the suspected lesions were biopsied.

Secondary Outcomes

  • The sensitivity, positive predictive value, and negative predictive value.(4 months)

Study Sites (1)

Loading locations...

Similar Trials